


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:12Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406186" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406186</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="c97037769" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406186</article-id><article-id pub-id-type="pmcid-ver">PMC12406186.1</article-id><article-id pub-id-type="pmcaid">12406186</article-id><article-id pub-id-type="pmcaiid">12406186</article-id><article-id pub-id-type="pmid">40797268</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c01073</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>N&#8209;Heterocyclic
Carbenes as Ligands to <sup>198</sup>Au(I)-Radiolabeled Compounds:
A New Platform for Radiopharmaceutical
Design</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e25-autogenerated"><contrib id="ath1" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6511359</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1348-0309</contrib-id><name name-style="western"><surname>Spreckelmeyer</surname><given-names initials="S">Sarah</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6591632</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1110-430X</contrib-id><name name-style="western"><surname>Thomas</surname><given-names initials="SR">Sophie R.</given-names></name><xref rid="aff2" ref-type="aff"/><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7563716</contrib-id><name name-style="western"><surname>Schuderer</surname><given-names initials="F">Franziska</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7563729</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4195-5810</contrib-id><name name-style="western"><surname>Pinto</surname><given-names initials="CIG">Catarina I. G.</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7586490</contrib-id><name name-style="western"><surname>de Andrade Querino</surname><given-names initials="AL">Ana Luiza</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6481166</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-2225-819X</contrib-id><name name-style="western"><surname>B&#246;hm</surname><given-names initials="FA">Felix A.</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6192653</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3665-4247</contrib-id><name name-style="western"><surname>Park</surname><given-names initials="M">Mihyun</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6618875</contrib-id><name name-style="western"><surname>Geppert</surname><given-names initials="C">Christopher</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6618876</contrib-id><name name-style="western"><surname>Gorges</surname><given-names initials="C">Christian</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2152666</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0646-1687</contrib-id><name name-style="western"><surname>Mendes</surname><given-names initials="F">Filipa</given-names></name><xref rid="aff5" ref-type="aff"/><xref rid="aff7" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">914086</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1599-9542</contrib-id><name name-style="western"><surname>Casini</surname><given-names initials="A">Angela</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff3" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Nuclear Medicine</institution>, <institution>Charit&#233;&#58872;Universit&#228;tsmedizin
Berlin, Freie Universit&#228;t Berlin, Humboldt-Universit&#228;t
zu Berlin, and Berlin Institute of Health</institution>, <addr-line>Augustenburger Platz 1</addr-line>, <postal-code>13353</postal-code>
<city>Berlin</city>, <country country="DE">Germany</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Department
of Inorganic Chemistry</institution>, <institution>University of Vienna</institution>, <addr-line>W&#228;hringer Stra&#223;e. 42</addr-line>, <postal-code>1090</postal-code>
<city>Vienna</city>, <country country="AT">Austria</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Medicinal
and Bioinorganic Chemistry, Department of Chemistry, School of Natural
Sciences</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9184</institution-id><institution>Technical University of Munich</institution></institution-wrap>, <addr-line>Lichtenbergstra&#223;e 4</addr-line>, <postal-code>85748</postal-code>
<city>Garching bei M&#252;nchen</city>, <country country="DE">Germany</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Pharmaceutical
Radiochemistry, Department of Chemistry, School of Natural Sciences</institution>, <institution>Technical University of Munich</institution>, <addr-line>Walther-Mei&#223;ner-Str. 3</addr-line>, <postal-code>85748</postal-code>
<city>Garching bei M&#252;nchen</city>, <country country="DE">Germany</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution content-type="dept">C<sup>2</sup>TN&#58872;Centro de Ci&#234;ncias
e Tecnologias Nucleares,
Instituto Superior T&#233;cnico</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">37809</institution-id><institution>Universidade
de Lisboa</institution></institution-wrap>, <postal-code>2695-066</postal-code>
<city>Lisboa</city>, <country country="PT">Portugal</country>
</aff><aff id="aff6">
<label>#</label>
<institution content-type="dept">Forschungsreaktor
TRIGA Mainz</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9182</institution-id><institution>Johannes Gutenberg-Universit&#228;t
Mainz</institution></institution-wrap>, <addr-line>Fritz-Strassmann-Weg 2</addr-line>, <postal-code>55128</postal-code>
<city>Mainz</city>, <country country="DE">Germany</country>
</aff><aff id="aff7">
<label>&#182;</label>
<institution content-type="dept">DECN&#58872;Departamento
de Engenharia e Ci&#234;ncias Nucleares, Instituto Superior T&#233;cnico</institution>, <institution>Universidade de Lisboa</institution>, <postal-code>2695-066</postal-code>
<city>Lisboa</city>, <country country="PT">Portugal</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>sarah.spreckelmeyer@charite.de</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>angela.casini@tum.de</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17516</fpage><lpage>17526</lpage><history><date date-type="received"><day>16</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>28</day><month>7</month><year>2025</year></date><date date-type="online"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-13"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-13">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c01073.pdf"/><abstract><p>The radionuclide <sup>198</sup>Au, with a half-life of
2.7 days,
emits &#947; radiation ideal for diagnostic purposes and generates
&#946;<sup>&#8211;</sup> particles suitable for effective cancer
radiotherapy, making it a perfect nuclide for &#8220;theranostics&#8221;.
However, the application of coordination compounds of Au&#173;(I)/Au&#173;(III)
in medicine is limited by their instability in vivo. Here, we explore
N-heterocyclic carbene (NHC) organometallic chemistry to stabilize <sup>198</sup>Au&#173;(I) in radiopharmaceuticals. Thus, Au&#173;(I) NHC compounds
featuring different scaffolds were selected for <sup>198</sup>Au radiolabeling.
Eventually, two compounds featuring imidazole (<bold>AuNHC-1</bold>) and theophylline (<bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub>)
scaffolds were successfully radiolabeled (radiochemical purity = 92.9%
and 40.2%, respectively). Instead, two peptidic Au&#173;(I) benzimidazolylidene
derivatives, capable of blood&#8211;brain barrier translocation in
vitro, were subjected to ligand exchange reactions under the applied
radiolabeling conditions. The obtained proof-of-concept results showed
that NHCs are suitable ligands to achieve isotope exchange in Au&#173;(I)
complexes. Overall, our work reveals the still untapped potential
of organometallic chemistry in radiopharmaceutical design.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c01073_0010.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c01073_0008.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>HORIZON EUROPE European Innovation Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100018703</institution-id></institution-wrap></funding-source><award-id>101129886</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c01073</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c01073</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>e5377c73eb722ba74241bdc93d48d47eb5c55959a20d5d47cbb20e0b6c0d7329</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The position of Au in the Periodic Table
of the Elements is unique
owing to its large relativistic effects, increased ionization energies,
and high redox potential, which set it apart from other neighboring
elements.<xref rid="ref1" ref-type="bibr"/> Particularly in the case of
Au&#173;(I) complexes, relativistic effects together with the lanthanide
contraction (reducing the covalent radius of Au&#173;(I)) strongly influence
their geometric features (linear geometry), their electronic structure,
and overall reactivity (&#8220;soft&#8221; Lewis acid). Accordingly,
Au&#173;(I) complexes bind preferentially to &#8220;soft&#8221; electron
donor elements like P and S. Steric factors allowing Au&#173;(I) compounds
also have a marked tendency to interact with neighboring Au&#173;(I) centers
to give &#8220;<italic toggle="yes">aurophilic</italic>&#8221; interactions.<xref rid="ref2" ref-type="bibr"/> On the other hand, for Au&#173;(III), the relativistic
effects are much less pronounced, and gold in this oxidation state
displays all of the characteristics of a transition metal, adopting
almost exclusively the square-planar coordination geometry common
to other d<sup>8</sup> ions, and its compounds are markedly different
in terms of structure and reactivity from those of Au&#173;(I).<xref rid="ref3" ref-type="bibr"/> Due to such properties, the chemistry of gold
has been one of the most striking research themes of recent times,
leading to the development of gold-based molecules and materials for
different uses.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#8722;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content>
</p><p>Among its noticeable properties, the radiochemistry of Au
is also
of potential interest for biomedical applications. Of the radioisotopes
of Au, both <sup>198</sup>Au and <sup>199</sup>Au are medically useful
because of their desirable nuclear properties.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/>
</named-content>
<sup>199</sup>Au has a 3.14 day half-life and emits &#946;<sup>&#8211;</sup> particles (<italic toggle="yes">E</italic>
<sub>max</sub> = 452 keV) plus &#947;
photons (<italic toggle="yes">E</italic>
<sub>&#947;</sub> = 158 keV, 72% and 208
keV, 22%), which are well suited to noninvasive single-photon emission
computed tomography (SPECT) imaging.<xref rid="ref11" ref-type="bibr"/>
<sup>198</sup>Au has a 2.7 day half-life and decays by emission of &#946;<sup>&#8211;</sup> particles (<italic toggle="yes">E</italic>
<sub>max</sub> = 1.37
MeV) and &#947; photons (<italic toggle="yes">E</italic>
<sub>&#947;</sub> = 412
keV, 98.9%). Although <sup>198</sup>Au has been used for both SPECT
and Cerenkov luminescence imaging, its abundant moderate-energy &#946;<sup>&#8211;</sup> emission and high-energy &#947; emission make it
more suitable for therapeutic applications rather than for imaging.
The production of carrier-added <sup>198</sup>Au takes place in a
reactor via the reaction of <sup>197</sup>Au&#173;(n,gamma)<sup>198</sup>Au, whereas <sup>199</sup>Au can be obtained no-carrier added via <sup>198</sup>Pt&#173;(n,gamma)<sup>199</sup>Pt, (30 min half-life), which subsequently
decays via beta emission to <sup>199</sup>Au. For potential application
in radionuclide therapy, a metal complex must be thermodynamically
favored, as well as kinetically stable to ligand substitution and
reductive decomposition. Unfortunately, the majority of Au&#173;(I)/Au&#173;(III)
coordination compounds show limitations with respect to stability
in physiological conditions in terms of kinetic lability, propensity
to ligand exchange reactions with biological nucleophiles (e.g., water
and protein thiolates),<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> and redox stability.
Both Au&#173;(I) and Au&#173;(III) coordination complexes can be reduced to Au(0)
in a physiological environment, resulting in the release of both the
free ligands and the metal, eventually leading to either a loss of
activity or possible side effects.</p><p>In an attempt to circumvent
such extensive <italic toggle="yes">speciation</italic> and to set the stage for
practically useful Au-based bioactive compounds,
the selection of the ligand framework of gold compounds is pivotal.
However, to date, only one report by Jurisson and co-workers has described
the application of radioactive <sup>198</sup>Au&#173;(III) molecular species
using (bis)&#173;thiosemicarbazone ligands.<xref rid="ref14" ref-type="bibr"/> Nonetheless, these ligand systems were unsuitable for in vivo application
due to the rapid degradation and reduction of Au&#173;(III) to Au&#173;(I) species.<xref rid="ref14" ref-type="bibr"/> Previous studies with tetradentate Schiff base
ligands were also shown to form <sup>198/199</sup>Au&#173;(III) complexes
in 95&#8211;100% yield, although no further stability and imaging
studies were conducted.<xref rid="ref15" ref-type="bibr"/> In 2014, a study
involving graphene oxide radiolabeled with a mixture of <sup>199</sup>Au&#173;(III) and <sup>198</sup>Au&#173;(III) ions tethered to graphene via binding
to amino groups of a 3-aminopropyl-trimethoxysilane linker showed
potential for SPECT tumor imaging.<xref rid="ref16" ref-type="bibr"/> Concerning
radioactive Au&#173;(I) complexes, early studies report on water-soluble
phosphine ligands, which were evaluated to form Au&#173;(I) complexes with
a tetrahedral geometry.<xref rid="ref17" ref-type="bibr"/> However, biodistribution
studies were performed in rats and showed extensive decomposition
due to ligand exchange reactions with intracellular thiols.<xref rid="ref18" ref-type="bibr"/> In another study, a dinuclear bisphosphino Au&#173;(I)
dithiocarbamate was successfully radiolabeled with <sup>198</sup>Au&#173;(I).<xref rid="ref19" ref-type="bibr"/> Unfortunately, this compound showed unfavorable
biodistribution in the lungs, liver, and spleen in rats. In a recent
study by Baitullina et al., coordination polyhedra with the motif
2,6-dipicolinoyl bis&#173;(<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dialkylthioureas)
were investigated among others toward their radiolabeling abilities
with <sup>68</sup>Ga, <sup>177</sup>Lu, and <sup>198</sup>Au&#173;(I).<xref rid="ref20" ref-type="bibr"/> As a result, radiolabeling experiments were
successful, but low stability in human serum albumin was observed,
hindering their further application.</p><p>To avoid metal ion complexation,
gold nanoparticles (AuNPs) have
also been used to incorporate <sup>198</sup>Au, enabling the quantification
of their in vivo biodistribution and tumor uptake in mouse models
by measuring the &#947; radiation from <sup>198</sup>Au decay and,
in some cases, by optical imaging through the detection of the Cerenkov
radiation.<named-content content-type="bibref-group">
<xref rid="ref21" ref-type="bibr"/>&#8722;<xref rid="ref22" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr"/>
</named-content> Interestingly, receptor-targeted <sup>198</sup>AuNPs have shown
important tumor reduction in xenograft models of prostate cancer.<xref rid="ref25" ref-type="bibr"/> In 2016, the first synthesis of AuNPs doped
with <sup>199</sup>Au atoms for targeted SPECT tumor imaging in a
mouse triple-negative breast cancer model was reported.<xref rid="ref26" ref-type="bibr"/> Despite these encouraging results, the use of
AuNPs for radionuclide therapy has some drawbacks, including challenging
administration routes, possible toxicity due to the accumulation of
colloids in off-target organs, and the inherent difficulties in analyzing
nanoscale materials.<named-content content-type="bibref-group">
<xref rid="ref27" ref-type="bibr"/>,<xref rid="ref28" ref-type="bibr"/>
</named-content> For example, the necessity to
stabilize the AuNPs and make them targeted toward the tumor site via
the judicious choice of the coating strategy requires extensive characterization
of the nanomaterials via different analytical and spectroscopic methods.</p><p>To further develop nuclear medicine applications of Au&#173;(I) complexes,
we envisaged that the use of organometallic chemistry to stabilize
the gold radioisotope via the formation of a direct metal&#8211;carbon
bond would be advantageous. Therefore, synthesizing a family of radioactive
organometallic <sup>198</sup>Au&#173;(I) N-heterocyclic carbene (NHC) complexes
was attempted starting from their cold analogs. It is worth mentioning
that NHCs have emerged as ideal ligands not only thanks to their remarkable
&#963;-donor and &#960;-back-donation ability,<xref rid="ref29" ref-type="bibr"/> necessary to stabilize Au&#173;(I) ions in physiological conditions,
but also since they perfectly fit the prerequisites for an efficient
(radio)&#173;pharmaceutical design enabling modulation of the metal compound&#8217;s
reactivity and physicochemical properties.<named-content content-type="bibref-group">
<xref rid="ref30" ref-type="bibr"/>&#8722;<xref rid="ref31" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref32" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref33" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref34" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref35" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref36" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref37" ref-type="bibr"/>
</named-content> To fine-tune the strength of the carbene&#8211;metal bond and,
therefore, the stability of the NHC-metal fragment in aqueous solution,
derivatization of the backbone scaffold has a central influence, whereas
modifications of the wingtip positions can change the steric properties
of the complex to protect the carbene-metal bond and enhance the stability
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>A). Furthermore,
by varying the side chains of the wingtip groups as well as of the
backbone positions, it is possible to influence the NHC lipophilicity
as well as its functionalization with bioactive moieties relevant
to (radio)&#173;pharmaceutical design (e.g., fluorophores for microscopy
and peptides/antibodies for targeting).<named-content content-type="bibref-group">
<xref rid="ref38" ref-type="bibr"/>&#8722;<xref rid="ref39" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref40" ref-type="bibr"/>
</named-content> Beyond this versatility,
the ease of synthesis of Au&#173;(I) NHC complexes, combined with their
inherent stability, renders this family of organometallic compounds
very appealing.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>(A) General structure of Au&#173;(I) NHC complexes with possible
sites
for derivatization highlighted. (B) Structures of the Au&#173;(I) NHC compounds
investigated in this study: <bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub>, <bold>AuNHC-1</bold>, <bold>AuNHC-2</bold>, and bioconjugated compounds <bold>AuNHC-2-pep</bold> and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> (pep = <sc>d</sc>-PepH3-NH<sub>2</sub>).</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c01073_0001.jpg"/></fig><p>Here, we have selected organometallic bis-NHC Au&#173;(I)
complexes representative
of different families: namely, <bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub> ([Au&#173;(9-methylcaffeine-8-ylidene)<sub>2</sub>]<sup>+</sup>),
a cytotoxic complex capable of selectively stabilizing telomeric DNA
G-quadruplex structures,<xref rid="ref41" ref-type="bibr"/> and <bold>AuNHC-1</bold>, a water-soluble complex with a sulfonate group on one of the wingtips<xref rid="ref42" ref-type="bibr"/> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>B). Moreover, a novel bis-carbenic complex with carboxylic
acid groups on the backbone to allow for bioconjugation (<bold>AuNHC-2</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>B, <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>A) was also synthesized.
In a proof-of-concept experiment to demonstrate the potential of Au&#173;(I)
NHC complexes to develop peptide-targeted radiopharmaceuticals,<named-content content-type="bibref-group">
<xref rid="ref43" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>
</named-content>
<bold>AuNHC-2</bold> was conjugated to a peptide able to cross the
blood&#8211;brain barrier (BBB), <sc>
<bold>d</bold>
</sc>
<bold>-PepH3-NH</bold>
<sub>
<bold>2</bold>
</sub> (H<sub>2</sub>N-AGILKRW-NH<sub>2</sub>),
forming <bold>AuNHC-2-pep</bold> and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>B, <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>B).<xref rid="ref45" ref-type="bibr"/> The use of peptidic vectors to guide
radiopharmaceuticals to the brain is attractive for the imaging and
therapy of brain cancers. In this context, PepH3 has previously been
studied for its BBB translocation capability in vitro and in vivo.<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>,<xref rid="ref46" ref-type="bibr"/>
</named-content> Interestingly, the peptide was shown to cross the BBB via a receptor-independent
mechanism, namely, via adsorptive-mediated transcytosis,<xref rid="ref47" ref-type="bibr"/> due to the presence of positively charged amino
acid residues in its sequence. The two bioconjugated Au&#173;(I) complexes
were studied for their BBB-translocation capabilities using an in
vitro model. Further, a protocol to achieve [<sup>198</sup>Au]&#173;AuNHC
complexes was optimized for compounds <bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub>, <bold>AuNHC-1</bold>, and <bold>AuNHC-2</bold>, as
well as the targeted <bold>AuNHC-2-pep</bold>. For our preliminary
radiotracer studies, carrier-added <sup>198</sup>Au was used rather
than the high-specific-activity <sup>199</sup>Au due to easier production
and reduced cost.</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>(A) Synthesis Scheme of Compound<bold>AuNHC-2</bold>; (B) synthesis
of the Bioconjugated<bold>AuNHC-2-pep</bold> and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> by Amide Bond Formation on Solid Support
between <bold>AuNHC-2</bold> and <sc>
<bold>d</bold>
</sc>
<bold>-PepH3-NH</bold>
<sub>
<bold>2</bold>
</sub>, Followed by Cleavage from the Resin</title></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c01073_0007.jpg"/></fig></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Synthesis and Characterization
of Cold Au&#173;(I) NHC Complexes</title><p>Initially, the Au&#173;(I) NHC compounds
were synthesized according to
established (<bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub> and <bold>AuNHC-1</bold>)<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>
</named-content> or adapted (<bold>AuNHC-2</bold>, <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>A)<xref rid="ref48" ref-type="bibr"/> procedures and characterized by standard methods
(see the Experimental Section for details, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figures S1&#8211;S3</ext-link>). Moreover, they were purified by high-performance
liquid chromatography (HPLC), and UV chromatograms were recorded (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figures S4&#8211;S6</ext-link>). For the synthesis of <bold>AuNHC-2-pep</bold>, a typical amide coupling reaction between <bold>AuNHC-2</bold> and <sc>
<bold>d</bold>
</sc>
<bold>-PepH3-NH</bold>
<sub>
<bold>2</bold>
</sub> was performed on the resin (solid support) to
reduce the number of side reactions (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>B). After cleavage from the resin, the crude
reaction mixture was purified by reverse-phase HPLC (RP-HPLC) to obtain
both <bold>AuNHC-2-pep</bold> (5.6%, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figures S7&#8211;S9</ext-link>) and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> (6.8%, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figures S10&#8211;S14</ext-link>).</p></sec><sec id="sec2.2"><title>Evaluation of Au&#173;(I) Complexes
in an In Vitro BBB Cell Model</title><p>Further, the evaluation of
the ability of the two bioconjugated
Au&#173;(I) complexes to translocate the BBB was performed in the bEnd.3
cell model in vitro.<xref rid="ref49" ref-type="bibr"/> We selected the
brain endothelioma bEnd.3 murine cell line as a representative established
cell line due to its facile growth and ability to maintain BBB characteristics
and functional barriers. As described previously by us, this in vitro
BBB model was established by growing the bEnd.3 cells in fibronectin-coated
transwell filters enabling the growth of a tight monolayer of cells
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A).<xref rid="ref50" ref-type="bibr"/> Before exploring BBB translocation, a cell viability
assay was performed to assess the toxicity of the Au&#173;(I) complexes
in this cell line grown under normal culture conditions. No cytotoxicity
was observed after 24 h of incubation with compound concentrations
of 1&#8211;25 &#956;M (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figure S15</ext-link>). To
assess the ability of the complexes to translocate the in vitro BBB
model, bEnd.3 cells were exposed to different concentrations of <bold>AuNHC-2-pep</bold> and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> complexes for 30 min and 2 h, and the Au content in the apical
and the basolateral media was determined by inductively coupled plasma
mass spectrometry (ICP&#8211;MS). The translocation efficiency was
determined by the amount of Au detected in the basolateral medium
as a % of the total Au content recovered (apical + basolateral media)
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B).</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>(A) Scheme
of the in vitro BBB cellular model translocation assay
(created in BioRender). (B) Translocation of Au complexes in the in
vitro BBB model, expressed as % of the total compound recovered. Values
for TcPzPepH3 and GaNODAPepH3 are from ref <xref rid="ref46" ref-type="bibr" specific-use="ref-style=base-text"/>.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c01073_0002.jpg"/></fig><p>Overall, the ICP&#8211;MS
determination of the Au content showed
that both complexes can translocate the in vitro BBB cell model, although
to a different extent, with <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> presenting a higher translocation value. The amount of Au
recovered in the apical and basolateral media was always &gt;98% of
the
total applied, which suggests that no Au (and therefore, no Au&#173;(I)
complex) is retained intracellularly, nor in the insert. Additionally,
a post-translocation integrity assay was performed to evaluate the
integrity of the endothelial barrier by assessing the permeability
of fluorescently labeled dextran (FD) with a 4 kDa molecular weight
(FD4). No decrease in the integrity of the cell model (&gt;80%) was
detected,
ensuring that the Au&#173;(I) complexes were not promoting any disruption
of the BBB in the in vitro model. These data are in line with previous
studies whereby PepH3 bioconjugate tracers of <sup>99m</sup>Tc and <sup>67</sup>Ga showed BBB translocation values of &#8764;10&#8211;26%
after 5 h of incubation (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B).<xref rid="ref46" ref-type="bibr"/>
</p></sec><sec id="sec2.3"><title>
<sup>198</sup>Au-Radiolabeling of Au&#173;(I) NHC Complexes and Stability
Studies</title><p>Finally, we attempted the radiolabeling of selected
Au&#173;(I) NHC compounds according to the experimental protocol depicted
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A,B. The
results of <sup>198</sup>Au-radiolabeling are shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>, where the radio-HPLC chromatograms
are presented. The starting material [<sup>198</sup>Au]&#173;Au&#173;(THT)Cl (THT
= tetrahydrothiophene) has a retention time of 7.1 min (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A), whereas the radio-chromatogram
of complex [<sup>198</sup>Au]<bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub> (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>B)
shows the product peak at the expected retention time of t<sub>R</sub> = 8.0 min, matching the UV signal of the nonradioactive precursor
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>). However, the peak of the starting
material [<sup>198</sup>Au]&#173;Au&#173;(THT)Cl is still present, leading to
a radiochemical purity (RCP) of only 40.2%. Compound [<sup>198</sup>Au]<bold>AuNHC-1</bold> (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>C) shows a clear peak at <italic toggle="yes">t</italic>
<sub>R</sub> = 8.1 min, in agreement with the retention time of nonradioactive <bold>AuNHC-1</bold> in the UV chromatogram (<italic toggle="yes">t</italic>
<sub>R</sub> = 7.7 min, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>). The discrepancy
between <italic toggle="yes">t</italic>
<sub>R</sub> = 8.1 min and <italic toggle="yes">t</italic>
<sub>R</sub> = 7.7 min is likely due to the experimental setup of
the HPLC system, whereby the injected solution passes first through
the UV detector followed by the radioactivity detector. The resulting
RCP is 92.9%, as assessed by radio-HPLC. Further, the stability of
[<sup>198</sup>Au]<bold>AuNHC-1</bold> was assessed in the presence
of human serum albumin (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C): ca. 57% of the compound remained stable after 1 h of incubation.
With radio-HPLC, we confirmed the presence of our intact <sup>198</sup>Au-radiolabeled complex (<italic toggle="yes">t</italic>
<sub>R</sub> ca. 8 min)
and a minor new peak at <italic toggle="yes">t</italic>
<sub>R</sub> = 9.8 min (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figure S16</ext-link>).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Schematic experimental setup of (A) preparation
of [<sup>198</sup>Au]&#173;Au&#173;(THT)Cl and (B) <sup>198</sup>Au-radiolabeling
of Au&#173;(I) NHC
precursors. (C) Setup of the stability experiment with human serum
albumin (HSA). Quality control performed by radio-HPLC (created in
BioRender).</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c01073_0003.jpg"/></fig><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Radio-HPLC chromatogram of (A) [<sup>198</sup>Au]&#173;Au&#173;(THT)&#173;Cl
(blue
trace), (B) [<sup>198</sup>Au]<bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub>, (C) [<sup>198</sup>Au]<bold>AuNHC-1</bold>, (D) [<sup>198</sup>Au]<bold>AuNHC-2</bold>, and (E) [<sup>198</sup>Au]<bold>AuNHC-2-pep</bold> (red trace).</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c01073_0004.jpg"/></fig><p>Unfortunately, the radiolabeling
of <bold>AuNHC-2</bold> and <bold>AuNHC-2-pep</bold> did not lead
to the desired radiolabeled products
[<sup>198</sup>Au]<bold>AuNHC-2</bold> and [<sup>198</sup>Au]<bold>AuNHC-2-pep</bold>. In fact, while the retention time of the nonradioactive
complexes are <italic toggle="yes">t</italic>
<sub>R</sub> = 10.8 and 10.0 min for <bold>AuNHC-2</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figure S6</ext-link>) and <bold>AuNHC-2-pep</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">Figure S7</ext-link>), respectively, the radio-chromatograms
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>D,E) showed
radioactive species at <italic toggle="yes">t</italic>
<sub>R</sub> = ca. 9.2 min.
Moreover, in both cases, the presence of [<sup>198</sup>Au]&#173;Au&#173;(THT)&#173;Cl
is still detected.</p><p>In order to elucidate the nature of the observed
possible byproducts,
we conducted further stability experiments by HPLC electrospray ionization
mass spectrometry (HPLC-ESI-MS) on the two nonradioactive complexes
working in radiolabeling conditions (90 &#176;C for 10 min in dimethyl
sulfoxide (DMSO)/water/EtOH). In summary, when <bold>AuNHC-2</bold> and <bold>AuNHC-2-pep</bold> were heated to 90 &#176;C for 10 min
in DMSO, the compounds remained stable (middle traces in <xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig"/>
</xref>A,B and <xref rid="fig6" ref-type="fig"/>A,B, <italic toggle="yes">t</italic>
<sub>R</sub> = 9.4 min for <bold>AuNHC-2</bold> and <italic toggle="yes">t</italic>
<sub>R</sub> = 8.8 min for <bold>AuNHC-2-pep</bold>). However, when the [Au&#173;(THT)&#173;Cl] solution was added
and heated to 90 &#176;C for 10 min in DMSO, both compounds showed
the formation of different species due to ligand exchange reactions
of the parent Au&#173;(I) NHC compound. Specifically, we could observe the
formation of [Au&#173;(THT)&#173;(MeCN)]<sup>+</sup> and monocarbene [Au&#173;(NHC)&#173;(MeCN)]<sup>+</sup> adducts for both Au&#173;(I) NHC complexes (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>: <italic toggle="yes">t</italic>
<sub>R</sub> = 5.6 and
7.7 min, respectively, for <bold>AuNHC-2</bold> and <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>: <italic toggle="yes">t</italic>
<sub>R</sub> = 5.7 and 7.8 min, respectively, for <bold>AuNHC-2-pep</bold>).
Furthermore, both complexes exhibited a peak at 9.3/9.4 min, corresponding
to low molecular weight masses, most likely due to adducts between
DMSO and Au&#173;(THT)&#173;Cl. Finally, <bold>AuNHC-2-pep</bold> showed an additional
species at 8.0 min (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>), corresponding to the positively charged gold complex with
retainment of the monocarbene peptide ligand.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Stability of compound <bold>AuNHC-2</bold> in different conditions
studied by HPLC-ESI-MS. (A) Stack overlay of RP-HPLC chromatograms
of <bold>AuNHC-2</bold> with different treatment conditions. The runs
were performed with water (0.1 vol % trifluoroacetic acid (TFA)) and
MeCN (0.1 vol % TFA) at a gradient of 0&#8211;100 over 15 min. Peaks
with their corresponding retention times are color-coded depending
on the species formed. (B) Stacked ESI-MS spectra for isolated peaks
from RP-HPLC chromatograms with main species highlighted with the
corresponding structure.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c01073_0005.jpg"/></fig><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Stability of compound <bold>AuNHC-2-pep</bold> in different
conditions
studied by HPLC-ESI-MS. (A) Stack overlay of RP-HPLC chromatograms
of <bold>AuNHC-2-pep</bold> with different treatment conditions. The
runs were performed with water (0.1 vol % TFA) and MeCN (0.1 vol %
TFA) at a gradient of 0&#8211;100 over 15 min. Peaks with their corresponding
retention times are color-coded depending on the species formed. (B)
Stacked ESI-MS spectra for isolated peaks from RP-HPLC chromatograms
with main species highlighted with the corresponding structure.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c01073_0006.jpg"/></fig><p>Overall, our studies show that the efficiency of
the radiolabeling
protocol is highly susceptible to the type of the NHC scaffold, e.g.,
imidazolium- vs benzimidazole-based NHC, type of wingtip groups, and
overall steric hindrance at the carbenic center. The nature of the
NHC affects both the efficiency of the isotope exchange process and
the stability of the resulting radioactive species. Further studies
are necessary to obtain structure&#8211;activity relationships and
fully unravel the determinants in the obtainment of <sup>198</sup>Au&#173;(I) NHC complexes. Moreover, optimization of the radiolabeling
protocol could be envisaged to avoid the observed speciation effects
for specific compounds. For example, the generation of <sup>198</sup>Au&#173;(I) precursors using less nucleophilic ligands compared to THT
could be explored.</p></sec></sec><sec id="sec3"><title>Conclusions</title><p>Due to the lack of stability
of previously reported radioactive
Au-coordination complexes, there are currently no <sup>198/199</sup>Au-radiopharmaceuticals in clinical use. In our study, we selected
five organometallic Au&#173;(I) compounds based on different NHC ligands,
endowed with higher stability with respect to classical coordination
complexes. In order to showcase the robustness of the NHC scaffold
with respect to functionalization, essential to achieve targeted radiopharmaceuticals,
two Au&#173;(I) complexes with benzimidazole-type NHCs were obtained, featuring
a short peptide sequence able to cross the BBB. The BBB translocation
capability of the two bioconjugated Au&#173;(I) compounds was ascertained
in vitro.</p><p>Of note, we achieved the <sup>198</sup>Au-radiolabeling
of two
Au&#173;(I) NHCs complexes in our selection based on imidazole (<bold>AuNHC-1</bold>) and theophylline (<bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub>)
scaffolds. Formation of radiolabeled products was also accomplished
in the case of benzimidazole-derived Au&#173;(I) NHCs; however, in this
case, extensive ligand exchange reactions prevented the obtainment
of the target radiolabeled compounds. Stability studies on the &#8220;cold&#8221;
Au&#173;(I) NHC compounds, conducted in the same conditions as the radiolabeling
experiments, enabled the identification of the different species formed
in solution and allowed us to attribute the observed speciation to
the addition of the highly nucleophilic [Au&#173;(I)&#173;(THT)&#173;Cl] precursor.</p><p>The obtained proof-of-concept studies showed that NHCs are suitable
ligands to achieve isotope exchange in Au&#173;(I) complexes, with imidazole
derivatives being most effectively radiolabeled and stable, also in
the presence of Au&#173;(THT)Cl and human serum albumin. Although further
studies are necessary to optimize the NHC ligand design to improve
stability in different conditions, our preliminary results, together
with the great variety of NHC ligands available in the literature,
give reasonable assumptions that Au&#173;(I) NHCs might be a game-changer
regarding access to radioactive gold compounds for radiopharmaceutical
applications. Radiolabeling of cytotoxic gold compounds may also be
relevant to achieve biodistribution studies in vivo to elucidate their
mode of actions and therapeutic effects in a variety of diseases.<xref rid="ref51" ref-type="bibr"/> Moreover, NHC ligands can also be envisaged
to stabilize Au&#173;(III) ions,<xref rid="ref52" ref-type="bibr"/> further broadening
the scope of radioactive gold compounds&#8217; design and applicability.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>General Procedure</title><p>Solvents and reagents (reagent grade)
were all commercially available and used without further purification.
Reactions using dry solvents were performed under nitrogen in flame-dried
glassware. Reactions involving silver or gold were carried out in
the absence of light. Flash column chromatography was performed on
silica gel 60A (particle size, 40&#8211;63 &#956;m). Additionally,
thin-layer chromatography was performed using Merck Millipore silica
gel 60 F-254 plates and analyzed with UV light. <sup>1</sup>H and <sup>13</sup>C&#173;{<sup>1</sup>H} NMR spectra were recorded on a Bruker AVANCE
DPX 400 at ambient temperature. Chemical shifts &#948; are reported
in parts per million (ppm), and coupling constants <italic toggle="yes">J</italic> are reported in Hertz (Hz), with residual <sup>1</sup>H and <sup>13</sup>C signals corresponding to the deuterated solvents as internal
standards. Elemental Analysis (EA) for C, H, and N was performed by
the microanalytical laboratory at the Technical University of Munich.
HR-ESI-MS was carried out on a Thermo Fisher Exactive Orbitrap mass
spectrometer equipped with a Thermo Fisher ESI source. Samples were
prepared in acetonitrile or a mixture of acetonitrile/H<sub>2</sub>O (1:1) and syringe-filtered before direct injection; ions were detected
in the positive mode. HR-Desorption Electrospray Ionization (DESI)-MS
experiments were performed on a Q Exactive Plus mass spectrometer
(Thermo Fisher Scientific Inc., Bremen, Germany) operated in the positive
ion mode. Data was obtained with a resolution of 70,000 within the
mass-to-charge (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>) range of 600&#8211;1000.
The capillary temperature was set to 320 &#176;C, the S-Lens RF value
to 100, and the maximum injection time to 250 ms. A mixture of HPLC
grade methanol and water (95:5, v/v) was used as the electrospray
solvent at a flow rate of 1.50 &#956;L/min and a spray voltage of
4.5 kV. The nebulizing gas pressure was set to 7 bar (Nitrogen N5.0).
The DESI geometrical parameters are as follows: a sprayer-to-sample
distance of 1.5 mm, a sprayer-to-inlet distance of 6 mm, a spray angle
of 75&#176;, and a collection angle of 10&#176;.</p><p>The Au&#173;(I) NHC
complexes (<bold>AuTMX</bold>
<sub>
<bold>2</bold>
</sub>, <bold>AuNHC-1</bold>, and (5-(ethoxycarbonyl)-1,3-diethyl-2,3-dihydro-1<italic toggle="yes">H</italic>-benzo&#173;[<italic toggle="yes">d</italic>]&#173;imidazole-2-yl)&#173;gold&#173;(I) chloride) and the
peptide, <sc>
<bold>d</bold>
</sc>
<bold>-PepH3-NH</bold>
<sub>
<bold>2</bold>
</sub> (H<sub>2</sub>N-aGilkrw-NH<sub>2</sub>), were synthesized
following the established protocols,<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref45" ref-type="bibr"/>,<xref rid="ref46" ref-type="bibr"/>,<xref rid="ref53" ref-type="bibr"/>
</named-content> and their purity was assessed to be &gt;97% (by EA or HPLC-HR-ESI-MS).</p></sec><sec id="sec4.2"><title>Synthesis and Characterization</title><sec id="sec4.2.1"><title>Synthesis of <bold>AuNHC-2</bold>
</title><p>
<bold>AuNHC-2</bold> was synthesized following an adapted
procedure published by Ott
and co-workers (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>A).<xref rid="ref48" ref-type="bibr"/> In detail, (5-(ethoxycarbonyl)-1,3-diethyl-2,3-dihydro-1<italic toggle="yes">H</italic>-benzo&#173;[<italic toggle="yes">d</italic>]&#173;imidazole-2-yl)&#173;gold&#173;(I) chloride
(118.5 mg, 0.25 mmol) and its corresponding ligand (93.6 mg, 0.25
mmol) were stirred with K<sub>2</sub>CO<sub>3</sub> (34.6 mg, 0.25
mmol) in a DCM/MeOH (1:1, 6 mL) mixture at room temperature for 12
h. The mixture was subsequently filtered before the product was isolated
by using column chromatography (DCM/MeOH 9:1). Yield: 125 mg (0.15
mmol, 74%) of orange powder. The deprotection of <bold>AuNHC-2</bold> was then performed using a modified procedure published by Crudden
and co-workers (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>A).<xref rid="ref54" ref-type="bibr"/>
<bold>AuNHC-2</bold> (28 mg, 0.034
mmol) and NaOH (5.5 mg, 0.138 mmol) were heated to 90 &#176;C for
1 h in EtOH/H<sub>2</sub>O (1:1, 10 mL). After cooling, EtOH was removed
under reduced pressure before acidification with 1 M HCl to obtain
pH 1&#8211;2. The aqueous solvent was subsequently removed under
reduced pressure, and the resulting solid was washed with methanol
until the filtrate became colorless. Yield: 14 mg (0.018 mmol, 55%)
white powder. Purity &gt;95%.</p><p>
<sup>1</sup>H NMR (400 MHz, DMF-<italic toggle="yes">d</italic>
<sub>7</sub>): &#948; 8.59 (s, 2H, Ar), 8.23 (dd, <italic toggle="yes">J</italic> = 8.6, 1.4 Hz, 2H, Ar), 8.15 (d, <italic toggle="yes">J</italic> =
8.6 Hz, 2H, Ar), 4.90 (dq, <italic toggle="yes">J</italic> = 22.6, 7.3 Hz, 8H,
NC<italic toggle="yes">H</italic>
<sub>2</sub>CH<sub>3</sub>), 1.70 (q, <italic toggle="yes">J</italic> = 6.9 Hz, 12H, NCH<sub>2</sub>C<italic toggle="yes">H</italic>
<sub>3</sub>).</p><p>
<sup>13</sup>C NMR (101 MHz, DMF-<italic toggle="yes">d</italic>
<sub>7</sub>): &#948; 193.44 (2C, N<italic toggle="yes">C</italic>N), 168.03
(2C, <italic toggle="yes">C</italic>OO), 136.87 (2C, <italic toggle="yes">C</italic>(Ar)), 134.05
(2C, <italic toggle="yes">C</italic>(Ar)), 129.09 (2C, <italic toggle="yes">C</italic>(Ar)),
127.07 (2C, <italic toggle="yes">C</italic>(Ar)&#173;H), 114.99 (2C, <italic toggle="yes">C</italic>(Ar)&#173;H), 113.39 (2C, <italic toggle="yes">C</italic>(Ar)&#173;H), 45.11 (2C, N<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 45.00 (2C, N<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 16.98 (2C, NCH<sub>2</sub>
<italic toggle="yes">C</italic>H<sub>3</sub>), 16.78
(2C, NCH<sub>2</sub>
<italic toggle="yes">C</italic>H<sub>3</sub>).</p><p>HR-ESI-MS
(CH<sub>3</sub>CN, pos. mode): C<sub>24</sub>H<sub>28</sub>AuN<sub>4</sub>O<sub>4</sub>
<sup>+</sup> (<bold>AuNHC-2</bold>) [M+]: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> = exp 633.1749 (calcd 633.1775).</p><p>EA: Calcd for C<sub>24</sub>H<sub>30</sub>AuIN<sub>4</sub>O<sub>5</sub> (<bold>AuNHC-2</bold> + 2H<sub>2</sub>O) [%] C, 36.20; H,
4.05; N, 7.04. Found [%]: C, 36.10; H, 3.89; N, 6.93.</p></sec><sec id="sec4.2.2"><title>Synthesis
of <bold>AuNHC-2-pep</bold> and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub>
</title><p>
<bold>AuNHC-2</bold> (1.5 equiv,
0.02 mmol) was dissolved in 4 mL of dimethylformamide together with
2-(1<italic toggle="yes">H</italic>-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium
tetrafluoroborate (TBTU, 1.5 equiv, 0.02 mmol) and 1-Hydroxy-7-azabenzotriazole
(HOAt, 1.5 equiv, 0.02 mmol), and the pH was adjusted to pH = 9 with <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-diisopropylethylamine (DIEA, 7.8 equiv,
0.10 mmol) (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>B). The coupling to the <sc>
<italic toggle="yes">n</italic>
</sc>-terminus of <sc>
<bold>d</bold>
</sc>
<bold>-PepH3-NH</bold>
<sub>
<bold>2</bold>
</sub> (H<sub>2</sub>N-aGilkrw-NH<sub>2</sub>) via manual solid-phase peptide
synthesis was performed over 18 h at r.t. After cleavage off the resin
using 10 mL of TFA/Triisopropyl silane/H<sub>2</sub>O (95/2.5/2.5)
for 1.5 h (30 min fraction 1 + 1 h fraction 2; 5 mL each) and evaporation
of the solvent under nitrogen current, the crude product was purified
using RP-HPLC (30&#8211;70% MeCN (+5% H<sub>2</sub>O, + 0.1% TFA)/H<sub>2</sub>O (0.1% TFA) over 30 min). This resulted in 13.5% (1.7 &#956;mol)
of unreacted <bold>AuNHC-2</bold>, 5.6% (0.71 &#956;mol) of monopeptide-NHC
(<bold>AuNHC-2-pep</bold>), and 6.8% (0.87 &#956;mol) of dipeptide-NHC
(<bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub>), which were characterized
by RP-HPLC and either HR-DESI-MS or ESI-MS. The purity of both products
is &gt;95%.</p><p>HR-DESI-MS: Calcd for C<sub>64</sub>H<sub>95</sub>AuN<sub>17</sub>O<sub>10</sub> (<bold>AuNHC-2-pep</bold>) [M + 2H]<sup>2+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> = exp 728.8509 (calcd
728.8509).</p><p>ESI-MS: Calcd for C<sub>104</sub>H<sub>158</sub>AuN<sub>30</sub>O<sub>16</sub> (<bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub>)&#173;([M + 3H]<sup>3+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">Z</italic> =
761.0 (calcd 762.1882).</p></sec></sec><sec id="sec4.3"><title>Biological Assays</title><sec id="sec4.3.1"><title>Cell Culture</title><p>Murine brain endothelial cells, bEnd.3
(American Type Culture Collection, CRL-2299), were cultured in Dulbecco&#8217;s
Modified Eagle&#8217;s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) (all from Gibco, Thermo Fisher Scientific) in a
humidified atmosphere of 5% CO<sub>2</sub> at 37 &#176;C. The cells
were tested for mycoplasma using the LookOut mycoplasma polymerase
chain reaction Detection kit (Sigma-Aldrich, Merck). To obtain the
in vitro BBB model, 200 &#956;L of a cell suspension with 5000 cells
was seeded in the apical side of fibronectin-coated tissue culture
polyethylene terephthalate inserts (pore size of 1 &#956;m) for 24-well
plates (Corning, Merck), and 500 &#956;L of complete culture medium
was added to the basal side of the inserts. The cells were grown for
10 days, and the media of both the apical and basal sides were changed
every other day.<named-content content-type="bibref-group">
<xref rid="ref46" ref-type="bibr"/>,<xref rid="ref50" ref-type="bibr"/>
</named-content>
</p></sec><sec id="sec4.3.2"><title>BBB Translocation Assay</title><p>bEnd.3 cells grown in the culture
inserts for 10 days were incubated with 200 &#956;L of 1 or 5 &#956;M <bold>AuNHC-2-pep</bold> and <bold>AuNHC-2-pep</bold>
<sub>
<bold>2</bold>
</sub> in the culture medium on the apical side for 30 min or 2 h.
The basal side of the inserts was incubated with 500 &#956;L of a
regular culture medium. After incubation, samples from both the apical
and basal sides were collected and analyzed by ICP&#8211;MS for quantification
of the Au content. Control inserts cultured with the regular culture
medium or with DMSO were also analyzed. For the ICP&#8211;MS analysis,
the samples were incubated for 24 h with a mixture of HNO<sub>3</sub> and HCl (1:3) and diluted with ultrapure water to 10 mL. The samples
were analyzed in a Thermo ICP&#8211;MS X series spectrometer, equipped
with an autosampler Cetac ASX-560, with a Mira Mist nebulizer (Burgener),
and a conical nebulization chamber, cooled with a Peltier system to
3 &#176;C (plasma power: 1400 W; plasma argon flow: 14 L/min; auxiliary
gas flow: 1 L/min; and sample rate: 1 mL/min). Calibration of the
equipment was performed with successive dilutions of a standard ICPMS
71 C (INORGANIC VENTURE) in 1:100 solution of HNO<sub>3</sub>/HCl
(1:3). One to two replicates were analyzed.</p></sec><sec id="sec4.3.3"><title>BBB Integrity Assay</title><p>To evaluate the integrity of the
BBB in vitro model after the translocation assay, the fluorescent
probe fluorescein isothiocyanate-dextran with a molecular weight of
4 kDa (FD4, Sigma-Aldrich) was used. Initially, the FD4 probe was
diluted in transport medium (DMEM FluoroBrite supplemented with 10%
FBS, both from Gibco and Thermo Fisher Scientific) to a final concentration
of 25 &#956;g/mL. Cells were rinsed twice with phosphate-buffered
saline and once with the transport medium. Then, bEnd.3 cells were
incubated with 200 &#956;L of the diluted FD4 in the apical side
and with 500 &#956;L of regular transport medium in the basal side.
After an incubation time of 2 h at 37 &#176;C, 5% CO<sub>2</sub> samples
from both the apical and the basal sides were collected, and their
fluorescence was measured (ex. 493 nm/em. 560 nm) in a microplate
reader (Varioskan Lux multimode, Thermo Fisher Scientific). Empty
inserts were used as controls. Only cell inserts with integrity values
above 80% were considered.</p></sec><sec id="sec4.3.4"><title>Viability Assay</title><p>The cytotoxicity
of the complexes in
the bEnd.3 cell line was evaluated using the CellTiter-Glo Cell Viability
Assay (Promega). Cells were seeded in 96-well plates at a density
of 2 &#215; 10<sup>4</sup> cells per well in 200 &#956;L of culture
medium and cultured overnight for optimal adherence. Stock solutions
of the complexes, freshly prepared in DMSO before each experiment,
were diluted in the medium with serial dilutions added to the wells
before incubation was performed at 37 &#176;C/5% CO<sub>2</sub> for
24 h. The percentage of DMSO in the cell culture medium did not exceed
2.5%. After 24 h, 100 &#956;L of culture medium was removed from
each well and replaced with 40 &#956;L of the CellTiter-Glo Cell
Viability Assay. After 15 min of incubation with agitation, 100 &#956;L
was transferred to a 96-well white bottom plate, and the luminescence
was measured using a microplate reader (Varioskan LUX multimode microplate
reader, Thermo Scientific). Each tested condition was determined in
at least 4 replicates.</p></sec></sec><sec id="sec4.4"><title>Radiolabeling</title><sec id="sec4.4.1"><title>Preparation of [<sup>198</sup>Au]&#173;Au&#173;(I)&#173;(THT)&#173;Cl</title><p>1.4 mg
or 2.8 mg of a solid gold bar was irradiated for up to approximately
10 min at a flux of 1.6 &#215; 10<sup>12</sup> n/cm<sup>2</sup> s
at the University of Mainz in the research reactor TRIGA to obtain
1 MBq of <sup>198</sup>Au. [<sup>198</sup>Au]&#173;Au&#173;(0) was dissolved in
40 &#956;L of aqua regia and heated up for 2 min at 90 &#176;C until
complete dissolution (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A). Afterward, the aqua regia was evaporated to dryness. The
solid was redissolved in 400 &#956;L of ultrapure water and 200 &#956;L
of ethanol to give a yellow solution of AuCl<sub>4</sub>
<sup>&#8211;</sup>. 10 &#956;L of THT was then added, resulting in a color change
of the solution from yellow to colorless, typical of Au&#173;(I) formation.
[<sup>198</sup>Au]&#173;Au&#173;(I)&#173;(THT)Cl was used without further purification.</p></sec><sec id="sec4.4.2"><title>Radiolabeling of Au&#173;(I) NHCs</title><p>For the manual radiolabeling
of the different Au&#173;(I) NHCs, a 2 mL reaction vial was used. 100 &#956;L
of the cold Au&#173;(I) NHC precursor (1 mg/100 &#956;L DMSO) was mixed
with 100 &#956;L of [<sup>198</sup>Au]&#173;Au&#173;(THT)Cl (approximately 120
KBq, in water/ethanol 66/33) and heated up to 90 &#176;C for 10 min
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B).</p></sec><sec id="sec4.4.3"><title>Quality
Control</title><p>For radio-HPLC, 40 &#956;L of the
final preparation was diluted with water to 90 &#956;L. 90 &#956;L
was injected into the HPLC system via an autosampler.</p><p>Analytical
HPLC was performed using a Shimadzu gradient system (Kyoto, Japan)
equipped with a SPD-20A UV/vis detector. The column for radio-HPLC
(RSC Gel C18ec, 125 &#215; 4.0 mm, 5 &#956;m) was purchased from
R. Sauerbrey Chromatographie (D-reinhardshagen). Eluents for all HPLC
operations were water (solvent A) and acetonitrile (solvent B), both
containing 0.1 vol % TFA with a gradient of 0&#8211;15 min 0&#8211;100%
B, 15&#8211;20 min 100% B, and 20&#8211;22 min 100&#8211;0% B.
Radioactivity was detected via a HERM LB 500 NaI detector and a Flowstar2
LB514 detector (Berthold Technologies, Bad Wildbad, Germany). A &#947;-counter
(PerkinElmer, Waltham, MA, USA) was used for the analysis of iTLC
experiments.</p></sec></sec><sec id="sec4.5"><title>Stability Studies with HSA</title><p>Assessment
of <sup>198</sup>Au NHC compounds&#8217; stability was performed
using human serum
albumin (H4522-100ML, Sigma-Aldrich), as depicted in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C. In detail, 100 &#956;L
of the respective radiolabeled Au&#173;(I) NHC complex was incubated with
100 &#956;L of human serum albumin at room temperature for 1 h. The
protein was precipitated with 100 &#956;L of ice-cold ethanol and
100 &#956;L of ice-cold acetonitrile. After centrifugation, the precipitate
(&#8220;bound to HSA&#8221;) and supernatant (&#8220;not bound
to HSA&#8221;) were analyzed separately with a gamma counter, and
the supernatant was additionally analyzed via radio-HPLC. The percentage
of stability was calculated from the ratio &#8220;bound to HSA&#8221;
vs &#8220;not bound to HSA&#8221; and taking into account the radiochemical
yield observed of the initial radiolabeling and &#8220;not bound
to HSA&#8221; fraction that was analyzed via radio-HPLC.</p></sec><sec id="sec4.6"><title>Stability Studies
of Nonradioactive Au&#173;(I) NHC Complexes</title><p>To replicate the experimental
conditions of the radiolabeled complexes,
the same conditions were used to prepare [Au&#173;(THT)&#173;Cl], except with
no prior irradiation of the gold bar. In detail, solid Au(0) (1 mg)
was dissolved in 40 &#956;L of aqua regia and heated to 90 &#176;C
for 2 min until complete dissolution. Afterward, the aqua regia was
evaporated to dryness, and the solid was redissolved in 400 &#956;L
of ultrapure water and 200 &#956;L of EtOH to give a yellow solution
of tetrachloroaurate. Thus, 10 &#956;L of THT was added, and the
solution changed from yellow to colorless, as previously observed. <bold>AuNHC-2</bold> or <bold>AuNHC-2-pep</bold> (1 mM in DMSO) was then
mixed with 100 &#956;L of [Au&#173;(THT)&#173;Cl] solution and heated to 90 &#176;C
for 10 min. The samples (40 &#956;L) were then diluted in 90 &#956;L
of Milli-Q water and filtered before measuring.</p><p>Analytical HPLC
measurements were performed using Shimadzu gradient systems (Kyoto,
Japan) equipped with an SPD-20A UV&#8211;vis detector. The column
(MultoKrom 100-5C18, 125 &#215; 4.6 mm) was purchased from CS-Chromatographie
Service GmbH (Langerwehe, Germany). Eluents for all HPLC operations
were water (solvent A) and acetonitrile (solvent B), both containing
0.1 vol % TFA with a gradient of 0&#8211;15 min 0&#8211;100% B,
15&#8211;20 min 100% B, and 20&#8211;22 min 100&#8211;0% B. ESI-MS
was carried out on an expression<sup>L</sup> CMS mass spectrometer
(Advion Ltd., Harlow, UK) equipped with a quadrupole analyzer and
an electron spray ionizer, also in the positive mode.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01073_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01073_si_002.csv" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>The authors acknowledge the funding
from the EU
Horizon Europe Research and Innovation Program, the EIC Pathfinder
Open Network &#8220;SMARTdrugs&#8221; (grant agreement ID: 101129886).
S.S. acknowledges the Berlin University Alliance for the Career Development
Award 2022 (421_CDA2_10_CHA). S.R.T. acknowledges the FWF (Austrian
Science Fund) for the ESPRIT fellowship (10.55776/ESP708). F.M. and
C.I.G.P. acknowledge FCT Portugal for UID/Multi/04349/2010 to C2TN,
FCTAustin for grant 2022.15449.UTA to F.M., and Ph.D. Fellowship 2020.07119.BD
to C.I.G. Pinto.</p></ack><notes id="notes1" notes-type="si"><p>The Supporting Information
is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01073?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01073</ext-link>.<list list-type="simple" id="silist"><list-item><p>
<sup>1</sup>H NMR of AuNHC-2
in DMF-<italic toggle="yes">d</italic>
<sub>7</sub>; <sup>13</sup>C NMR of AuNHC-2
in DMF-<italic toggle="yes">d</italic>
<sub>7</sub>; HR-ESI-MS of AuNHC-2; UV chromatogram
of AuTMX<sub>2</sub>; UV chromatogram of AuNHC-1; UV chromatogram
of AuNHC-2;
UV chromatogram of AuNHC-2-pep; HR-DESI-MS of AuNHC-2-pep; <sup>1</sup>H NMR (500 MHz) of AuNHC-2-pep in DMF-<italic toggle="yes">d</italic>
<sub>7</sub>; UV chromatogram of AuNHC-2-pep<sub>2</sub>; ESI-MS of AuNHC-2-pep<sub>2</sub>; <sup>1</sup>H NMR (500 MHz) of AuNHC-2-pep<sub>2</sub> in
DMF-<italic toggle="yes">d</italic>
<sub>7</sub>; <sup>1</sup>H&#8211;<sup>1</sup>H correlation spectroscopy NMR (500 MHz) of AuNHC-2-pep<sub>2</sub> in DMF-<italic toggle="yes">d</italic>
<sub>7</sub>; <sup>1</sup>H&#8211;<sup>1</sup>H nuclear Overhauser enhancement spectroscopy NMR (500 MHz)
of AuNHC-2-pep<sub>2</sub> in DMF-<italic toggle="yes">d</italic>
<sub>7</sub>;
cytotoxicity studies; and radio-HPLC chromatogram of [<sup>198</sup>Au]&#173;AuNHC-1 in human serum albumin after precipitation of proteins
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>Molecular
formula strings (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01073/suppl_file/jm5c01073_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item></list>
</p></notes><notes id="notes3" notes-type="author-contributions"><label>&#8711;</label><p>S.S.,
S.R.T., and F.S. co-first authors.</p></notes><notes id="notes2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>MeCN</term><def><p>acetonitrile</p></def></def-item><def-item><term>TBTU</term><def><p>2-(1<italic toggle="yes">H</italic>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium
tetrafluoroborate</p></def></def-item><def-item><term>BBB</term><def><p>blood&#8211;brain barrier</p></def></def-item><def-item><term>CO<sub>2</sub>
</term><def><p>carbon dioxide</p></def></def-item><def-item><term>DCM</term><def><p>dichloromethane</p></def></def-item><def-item><term>DMF</term><def><p>dimethylformamide</p></def></def-item><def-item><term>DMSO</term><def><p>dimethyl sulfoxide</p></def></def-item><def-item><term>DIEA</term><def><p>
<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-diisopropylethylamine</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#8217;s modified Eagle&#8217;s medium</p></def></def-item><def-item><term>EA</term><def><p>elemental analysis</p></def></def-item><def-item><term>EtOH</term><def><p>ethanol</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>FD</term><def><p>fluorescently labeled
dextran</p></def></def-item><def-item><term>AuNPs</term><def><p>gold
nanoparticles</p></def></def-item><def-item><term>Hz</term><def><p>hertz</p></def></def-item><def-item><term>HR-DESI-MS</term><def><p>high-resolution desorption electrospray ionization mass spectrometry</p></def></def-item><def-item><term>HR-ESI-MS</term><def><p>high-resolution
electrospray ionization mass spectrometry</p></def></def-item><def-item><term>HPLC-ESI-MS</term><def><p>high-performance liquid chromatography-electrospray
ionization mass spectrometry</p></def></def-item><def-item><term>HSA</term><def><p>human serum albumin</p></def></def-item><def-item><term>HCl</term><def><p>hydrochloric acid</p></def></def-item><def-item><term>HOAt</term><def><p>1-hydroxy-7-azabenzotriazole</p></def></def-item><def-item><term>ICP-MS</term><def><p>inductively coupled plasma mass spectrometry</p></def></def-item><def-item><term>
<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>
</term><def><p>mass-to-charge</p></def></def-item><def-item><term>MeOH</term><def><p>methanol</p></def></def-item><def-item><term>NHC</term><def><p>
<italic toggle="yes">N</italic>-heterocyclic carbenes</p></def></def-item><def-item><term>HNO<sub>3</sub>
</term><def><p>nitric acid</p></def></def-item><def-item><term>ppm</term><def><p>parts per million</p></def></def-item><def-item><term>PBS</term><def><p>phosphate buffered saline</p></def></def-item><def-item><term>PET</term><def><p>polyethylene terephthalate</p></def></def-item><def-item><term>PCR</term><def><p>polymerase chain
reaction</p></def></def-item><def-item><term>RCP</term><def><p>radiochemical
purity</p></def></def-item><def-item><term>RP-HPLC</term><def><p>reverse-phase
HPLC</p></def></def-item><def-item><term>SPECT</term><def><p>single-photon
emission computed tomography</p></def></def-item><def-item><term>NaOH</term><def><p>sodium hydroxide</p></def></def-item><def-item><term>SPPS</term><def><p>solid-phase peptide synthesis</p></def></def-item><def-item><term>THT</term><def><p>tetrahydrothiophene</p></def></def-item><def-item><term>TLC</term><def><p>thin-layer chromatography</p></def></def-item><def-item><term>TFA</term><def><p>trifluoroacetic acid</p></def></def-item><def-item><term>TIPS</term><def><p>triisopropyl silane</p></def></def-item><def-item><term>TNBC</term><def><p>triple-negative
breast cancer</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Raubenheimer</surname><given-names>H. G.</given-names></name><name name-style="western"><surname>Schmidbaur</surname><given-names>H.</given-names></name><article-title>The Late Start and Amazing Upswing in Gold Chemistry</article-title><source>J. Chem. Educ.</source><year>2014</year><volume>91</volume><fpage>2024</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1021/ed400782p</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Schmidbaur</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schier</surname><given-names>A.</given-names></name><article-title>A Briefing
on Aurophilicity</article-title><source>Chem. Soc. Rev.</source><year>2008</year><volume>37</volume><issue>9</issue><fpage>1931</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1039/b708845k</pub-id><pub-id pub-id-type="pmid">18762840</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Rocchigiani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bochmann</surname><given-names>M.</given-names></name><article-title>Recent Advances in
Gold&#173;(III) Chemistry: Structure,
Bonding, Reactivity, and Role in Homogeneous Catalysis</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><issue>14</issue><fpage>8364</fpage><lpage>8451</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c00552</pub-id><pub-id pub-id-type="pmid">32966741</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Fedeli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Im</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elia</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rotello</surname><given-names>V. M.</given-names></name><article-title>Nanomaterial-Based
Bioorthogonal Nanozymes for Biological
Applications</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><issue>24</issue><fpage>13467</fpage><lpage>13480</lpage><pub-id pub-id-type="doi">10.1039/D0CS00659A</pub-id><pub-id pub-id-type="pmid">34787131</pub-id><pub-id pub-id-type="pmcid">PMC8862209</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Karnwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar Sachan</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Devgon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Devgon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>G.</given-names></name><name name-style="western"><surname>Panchpuri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alshammari</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>G.</given-names></name><article-title>Gold Nanoparticles
in Nanobiotechnology:
From Synthesis to Biosensing Applications</article-title><source>ACS
Omega</source><year>2024</year><volume>9</volume><issue>28</issue><fpage>29966</fpage><lpage>29982</lpage><pub-id pub-id-type="doi">10.1021/acsomega.3c10352</pub-id><pub-id pub-id-type="pmid">39035946</pub-id><pub-id pub-id-type="pmcid">PMC11256298</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Hashmi</surname><given-names>A. S. K.</given-names></name><article-title>Introduction:
Gold Chemistry</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><issue>14</issue><fpage>8309</fpage><lpage>8310</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.1c00393</pub-id><pub-id pub-id-type="pmid">34315211</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Thomas</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A. N.</given-names></name><article-title>N-Heterocyclic carbenes
as &#8220;smart&#8221; gold
nanoparticle stabilizers: State-of-the art and perspectives for biomedical
applications</article-title><source>J. Organomet. Chem.</source><year>2021</year><volume>938</volume><fpage>121743</fpage><pub-id pub-id-type="doi">10.1016/j.jorganchem.2021.121743</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Moreno-Alc&#225;ntar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Picchetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><article-title>Gold Complexes in Anticancer Therapy:
From New Design Principles to Particle-Based Delivery Systems</article-title><source>Angew. Chem., Int. Ed.</source><year>2023</year><volume>62</volume><elocation-id>e202218000</elocation-id><pub-id pub-id-type="doi">10.1002/anie.202218000</pub-id><pub-id pub-id-type="pmid">36847211</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Cutler</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Hennkens</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Sisay</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huclier-Markai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>S. S.</given-names></name><article-title>Radiometals for Combined Imaging and Therapy</article-title><source>Chem. Rev.</source><year>2013</year><volume>113</volume><issue>2</issue><fpage>858</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1021/cr3003104</pub-id><pub-id pub-id-type="pmid">23198879</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Volkert</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Goeckeler</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Ehrhardt</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Ketring</surname><given-names>A. R.</given-names></name><article-title>Therapeutic Radionuclides:
Production and Decay Property Considerations</article-title><source>J. Nucl. Med.</source><year>1991</year><volume>32</volume><fpage>174</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">1988628</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Cutler</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Hennkens</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Sisay</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huclier-Markai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>S. S.</given-names></name><article-title>Radiometals for Combined Imaging and Therapy</article-title><source>Chem. Rev.</source><year>2013</year><volume>113</volume><issue>2</issue><fpage>858</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1021/cr3003104</pub-id><pub-id pub-id-type="pmid">23198879</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Djekovi&#263;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petrovi&#263;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bugar&#269;i&#263;</surname><given-names>Z. &#711;. D.</given-names></name><name name-style="western"><surname>Puchta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Eldik</surname><given-names>R.</given-names></name><article-title>Kinetics and Mechanism of the Reactions
of Au&#173;(III) Complexes with Some Biologically Relevant Molecules</article-title><source>Dalton Trans.</source><year>2012</year><volume>41</volume><issue>13</issue><fpage>3633</fpage><lpage>3641</lpage><pub-id pub-id-type="doi">10.1039/c2dt11843b</pub-id><pub-id pub-id-type="pmid">22318647</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Gamov</surname><given-names>G. A.</given-names></name><article-title>Complexation
of Gold&#173;(I) and Gold&#173;(III) in Solutions</article-title><source>Coord.
Chem. Rev.</source><year>2024</year><volume>520</volume><fpage>216162</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2024.216162</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Bottenus</surname><given-names>B. N.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rold</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>S. S.</given-names></name><article-title>Gold&#173;(III)
Bis-Thiosemicarbazonato Complexes: Synthesis, Characterization, Radiochemistry
and X-Ray Crystal Structure Analysis</article-title><source>Nucl.
Med. Biol.</source><year>2010</year><volume>37</volume><issue>1</issue><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2009.08.003</pub-id><pub-id pub-id-type="pmid">20122667</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Barnholtz</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Venkatesh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Ketring</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>S. S.</given-names></name><article-title>Syntheses
and Characterization
of Gold&#173;(III) Tetradentate Schiff Base Complexes. X-Ray Crystal Structures
of [Au&#173;(Sal2pn)]&#173;Cl&#183;2.5H2O and [Au&#173;(Sal2en)]&#173;PF6</article-title><source>Inorg. Chem.</source><year>2001</year><volume>40</volume><issue>5</issue><fpage>972</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1021/ic001073m</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Fazaeli</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akhavan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rahighi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aboudzadeh</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Afarideh</surname><given-names>H.</given-names></name><article-title>In Vivo SPECT Imaging of Tumors by
198,199Au-Labeled Graphene Oxide Nanostructures</article-title><source>Mater. Sci. Eng., C</source><year>2014</year><volume>45</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2014.09.019</pub-id><pub-id pub-id-type="pmid">25491820</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Berning</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Volkert</surname><given-names>W. A.</given-names></name><article-title>Hydroxymethyl Functionalized
Phosphanes as Building Blocks to New Water-Soluble Gold&#173;(I) Complexes
- Synthesis, Characterization, and X-Ray Crystal Structures of Novel
Tetrahedral [Au&#173;{P&#173;(CH2OH)&#173;3}&#173;4]+ and Trigonal Planar [Au&#173;(Ph2PCH2OH)&#173;3]+
Gold&#173;(I) Complexes</article-title><source>Chem. Ber.</source><year>1997</year><volume>130</volume><issue>7</issue><fpage>907</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1002/cber.19971300716</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Berning</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Volkert</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Higginbotham</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Ketring</surname><given-names>A. R.</given-names></name><article-title>198Au-Labeled Hydroxymethyl Phosphines
as Models for
Potential Therapeutic Pharmaceuticals</article-title><source>Nucl.
Med. Biol.</source><year>1998</year><volume>25</volume><issue>6</issue><fpage>577</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/S0969-8051(98)00023-7</pub-id><pub-id pub-id-type="pmid">9751426</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Kriel</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Szucs</surname><given-names>Z.</given-names></name><name name-style="western"><surname>van Staden</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Bester</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Mongane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lamprecht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rae</surname><given-names>W. I. D.</given-names></name><name name-style="western"><surname>Zeevaart</surname><given-names>J. R.</given-names></name><article-title>Biodistribution
of a Potential Chemotherapeutic, Dinuclearbisphosphinogold&#173;(I) Dithiocarbamate,
as Determined by Its 198Au Radiolabelled Analogue</article-title><source>J. Radioanal. Nucl. Chem.</source><year>2015</year><volume>303</volume><issue>3</issue><fpage>1949</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1007/s10967-014-3816-4</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Baitullina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Claude</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sucena</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Nisli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amthauer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Geppert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gorges</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abram</surname><given-names>U.</given-names></name><name name-style="western"><surname>da Silva
Maia</surname><given-names>P. I.</given-names></name><name name-style="western"><surname>Spreckelmeyer</surname><given-names>S.</given-names></name><article-title>Metallacages with 2,6-Dipicolinoylbis&#173;(N,N-Dialkylthioureas)
as Novel Platforms in Nuclear Medicine for 68Ga, 177Lu and 198Au</article-title><source>EJNMMI Radiopharm. Chem.</source><year>2023</year><volume>8</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s41181-023-00225-z</pub-id><pub-id pub-id-type="pmid">37982944</pub-id><pub-id pub-id-type="pmcid">PMC10661681</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Kannan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rahing</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pandrapragada</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Kattumuri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Casteel</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boote</surname><given-names>E.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K. V.</given-names></name><article-title>Nanocompatible Chemistry toward Fabrication
of Target-Specific
Gold Nanoparticles</article-title><source>J. Am. Chem. Soc.</source><year>2006</year><volume>128</volume><issue>35</issue><fpage>11342</fpage><lpage>11343</lpage><pub-id pub-id-type="doi">10.1021/ja063280c</pub-id><pub-id pub-id-type="pmid">16939243</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Chanda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kattumuri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zambre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Upendran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fent</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Casteel</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Boote</surname><given-names>E.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lever</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>R.</given-names></name><article-title>Bombesin Functionalized
Gold Nanoparticles Show in Vitro and in Vivo Cancer Receptor Specificity</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2010</year><volume>107</volume><issue>19</issue><fpage>8760</fpage><lpage>8765</lpage><pub-id pub-id-type="doi">10.1073/pnas.1002143107</pub-id><pub-id pub-id-type="pmid">20410458</pub-id><pub-id pub-id-type="pmcid">PMC2889350</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Black</surname><given-names>K. C. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luehmann</surname><given-names>H. P.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><article-title>Radioactive 198Au-Doped
Nanostructures with Different
Shapes for In Vivo Analyses of Their Biodistribution, Tumor Uptake,
and Intratumoral Distribution</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><issue>5</issue><fpage>4385</fpage><lpage>4394</lpage><pub-id pub-id-type="doi">10.1021/nn406258m</pub-id><pub-id pub-id-type="pmid">24766522</pub-id><pub-id pub-id-type="pmcid">PMC4358630</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><article-title>Radiolabeling
of Gold Nanocages for Potential Applications
in Tracking, Diagnosis, and Image-Guided Therapy</article-title><source>Adv. Healthcare Mater.</source><year>2021</year><volume>10</volume><fpage>2002031</fpage><pub-id pub-id-type="doi">10.1002/adhm.202002031</pub-id><pub-id pub-id-type="pmcid">PMC8289932</pub-id><pub-id pub-id-type="pmid">33470560</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Shukla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chanda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zambre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Upendran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Nune</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Casteel</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Vimal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boote</surname><given-names>E.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Engelbrecht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watkinson</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Carmack</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Lever</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>K. V.</given-names></name><article-title>Laminin
Receptor Specific Therapeutic Gold Nanoparticles (198AuNP-EGCg) Show
Efficacy in Treating Prostate Cancer</article-title><source>Proc.
Natl. Acad. Sci. U.S.A.</source><year>2012</year><volume>109</volume><issue>31</issue><fpage>12426</fpage><lpage>12431</lpage><pub-id pub-id-type="doi">10.1073/pnas.1121174109</pub-id><pub-id pub-id-type="pmid">22802668</pub-id><pub-id pub-id-type="pmcid">PMC3411993</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luehmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Detering</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harpstrite</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><article-title>Gold Nanoparticles Doped with 199Au Atoms and Their
Use for Targeted Cancer Imaging by SPECT</article-title><source>Adv.
Healthcare Mater.</source><year>2016</year><volume>5</volume><issue>8</issue><fpage>928</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1002/adhm.201500992</pub-id><pub-id pub-id-type="pmcid">PMC4836969</pub-id><pub-id pub-id-type="pmid">26865221</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Silva</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campello</surname><given-names>M. P. C.</given-names></name><name name-style="western"><surname>Paulo</surname><given-names>A.</given-names></name><article-title>Radiolabeled Gold Nanoparticles for
Imaging and Therapy of Cancer</article-title><source>Materials</source><year>2021</year><volume>14</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.3390/ma14010004</pub-id><pub-id pub-id-type="pmcid">PMC7792784</pub-id><pub-id pub-id-type="pmid">33375074</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Haume</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grellet</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#346;mia&#322;ek</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Butterworth</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Solov&#8217;yov</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Prise</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Golding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>N. J.</given-names></name><article-title>Gold Nanoparticles for Cancer Radiotherapy: A Review</article-title><source>Cancer Nano</source><year>2016</year><volume>7</volume><issue>8</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1186/s12645-016-0021-x</pub-id><pub-id pub-id-type="pmcid">PMC5095165</pub-id><pub-id pub-id-type="pmid">27867425</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Marchione</surname><given-names>D.</given-names></name><name name-style="western"><surname>Belpassi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bistoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Macchioni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tarantelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zuccaccia</surname><given-names>D.</given-names></name><article-title>The Chemical Bond in Gold&#173;(I) Complexes
with N-Heterocyclic Carbenes</article-title><source>Organometallics</source><year>2014</year><volume>33</volume><issue>16</issue><fpage>4200</fpage><lpage>4208</lpage><pub-id pub-id-type="doi">10.1021/om5003667</pub-id></element-citation></ref><ref id="ref30"><mixed-citation publication-type="book" id="cit30"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Schmidt</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western"><surname>Casini</surname>, <given-names>A.</given-names></string-name></person-group><article-title>Organometallic
Chemistry of Gold-Based Drugs</article-title>. In <source>Comprehensive
Organometallic Chemistry IV</source>; <publisher-name>Elsevier</publisher-name>, <year>2022</year>; pp <fpage>297</fpage>&#8211;<lpage>313</lpage>.<pub-id pub-id-type="doi">10.1016/B978-0-12-820206-7.00032-9</pub-id>.</mixed-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gust</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><article-title>Recent Development
of Gold&#173;(I) and Gold&#173;(III) Complexes as Therapeutic Agents for Cancer
Diseases</article-title><source>Chem. Soc. Rev.</source><year>2022</year><volume>51</volume><issue>13</issue><fpage>5518</fpage><lpage>5556</lpage><pub-id pub-id-type="doi">10.1039/D1CS00933H</pub-id><pub-id pub-id-type="pmid">35699475</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>T.</given-names></name><article-title>Modulating the Chemical Reactivity
of Gold Complexes in Living Systems: From Concept to Biomedical Applications</article-title><source>Acc. Chem. Res.</source><year>2023</year><volume>56</volume><issue>9</issue><fpage>1043</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.3c00037</pub-id><pub-id pub-id-type="pmid">37079555</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Zou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lok</surname><given-names>C. N.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z. F.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Che</surname><given-names>C. M.</given-names></name><article-title>Anticancer Metal-N-Heterocyclic Carbene Complexes of
Gold, Platinum and Palladium</article-title><source>Curr. Opin. Chem.
Biol.</source><year>2018</year><volume>43</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2017.10.014</pub-id><pub-id pub-id-type="pmid">29136524</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Porchia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pellei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marinelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tisato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Del Bello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>C.</given-names></name><article-title>New Insights in Au-NHCs
Complexes as Anticancer Agents</article-title><source>Eur. J. Med.
Chem.</source><year>2018</year><volume>146</volume><fpage>709</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.01.065</pub-id><pub-id pub-id-type="pmid">29407992</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Bannwart</surname><given-names>F.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Stifel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rueter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lode</surname><given-names>H. N.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>J. D. G.</given-names></name><name name-style="western"><surname>K&#252;hn</surname><given-names>F. E.</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>A.</given-names></name><article-title>A New Class of Gold&#173;(I)
NHC Complexes with Proapoptotic and Resensitizing Properties towards
Multidrug Resistant Leukemia Cells Overexpressing BCL-2</article-title><source>J. Med. Chem.</source><year>2024</year><volume>67</volume><issue>17</issue><fpage>15494</fpage><lpage>15508</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.4c01117</pub-id><pub-id pub-id-type="pmid">39196554</pub-id><pub-id pub-id-type="pmcid">PMC11403678</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Schuh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pfl&#252;ger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Citta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Folda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rigobello</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Bindoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>F.</given-names></name><article-title>Gold&#173;(I) Carbene
Complexes
Causing Thioredoxin 1 and Thioredoxin 2 Oxidation as Potential Anticancer
Agents</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><issue>11</issue><fpage>5518</fpage><lpage>5528</lpage><pub-id pub-id-type="doi">10.1021/jm300428v</pub-id><pub-id pub-id-type="pmid">22621714</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Mui</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Gallardo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elie</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Gubran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maluenda</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sana&#250;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>O.</given-names></name><name name-style="western"><surname>Contel</surname><given-names>M.</given-names></name><article-title>Titanocene-Gold
Complexes Containing N-Heterocyclic Carbene Ligands Inhibit Growth
of Prostate, Renal, and Colon Cancers in Vitro</article-title><source>Organometallics</source><year>2016</year><volume>35</volume><issue>9</issue><fpage>1218</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1021/acs.organomet.6b00051</pub-id><pub-id pub-id-type="pmid">27182101</pub-id><pub-id pub-id-type="pmcid">PMC4863200</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Citta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>F.</given-names></name><name name-style="western"><surname>Folda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Massimino</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Bindoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rigobello</surname><given-names>M. P.</given-names></name><article-title>Fluorescent
Silver&#173;(I) and Gold&#173;(I)-N-Heterocyclic Carbene Complexes with Cytotoxic
Properties: Mechanistic Insights</article-title><source>Metallomics</source><year>2013</year><volume>5</volume><issue>8</issue><fpage>1006</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1039/c3mt20260g</pub-id><pub-id pub-id-type="pmid">23661165</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Bertrand</surname><given-names>B.</given-names></name><name name-style="western"><surname>De Almeida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Der Burgt</surname><given-names>E. P. M.</given-names></name><name name-style="western"><surname>Picquet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Citta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Folda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rigobello</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Le Gendre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bodio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><article-title>New Gold&#173;(I)
Organometallic Compounds
with Biological Activity in Cancer Cells</article-title><source>Eur.
J. Inorg. Chem.</source><year>2014</year><volume>2014</volume><fpage>4532</fpage><lpage>4536</lpage><pub-id pub-id-type="doi">10.1002/ejic.201402248</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Luengo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marzo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Moreira</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gimeno</surname><given-names>M. C.</given-names></name><article-title>Synthesis
and Antiproliferative Study of Phosphorescent Multimetallic Re&#173;(I)/Au&#173;(I)
Complexes Containing Fused Imidazo&#173;[4,5-f]-1,10-Phenanthroline Core</article-title><source>Appl. Organomet. Chem.</source><year>2024</year><volume>38</volume><issue>10</issue><elocation-id>e6661</elocation-id><pub-id pub-id-type="doi">10.1002/aoc.6661</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Bertrand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pirrotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Monchaud</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bodio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Le Gendre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Warmerdam</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Jager</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Groothuis</surname><given-names>G. M. M.</given-names></name><name name-style="western"><surname>Picquet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><article-title>Caffeine-Based
Gold&#173;(I) N-Heterocyclic Carbenes as Possible Anticancer Agents: Synthesis
and Biological Properties</article-title><source>Inorg. Chem.</source><year>2014</year><volume>53</volume><issue>4</issue><fpage>2296</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1021/ic403011h</pub-id><pub-id pub-id-type="pmid">24499428</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Alm&#225;ssy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>B&#233;nyei</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Jo&#243;</surname><given-names>F.</given-names></name><article-title>Novel Sulfonated
N-Heterocyclic Carbene Gold&#173;(I) Complexes: Homogeneous Gold Catalysis
for the Hydration of Terminal Alkynes in Aqueous Media</article-title><source>Organometallics</source><year>2010</year><volume>29</volume><issue>11</issue><fpage>2484</fpage><lpage>2490</lpage><pub-id pub-id-type="doi">10.1021/om1001292</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Di
Santo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Santo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sviridenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Virgolini</surname><given-names>I.</given-names></name><article-title>Peptide Receptor Radionuclide Therapy Combinations
for Neuroendocrine Tumours in Ongoing Clinical Trials: Status 2023</article-title><source>Theranostics</source><year>2024</year><volume>14</volume><issue>3</issue><fpage>940</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.7150/thno.91268</pub-id><pub-id pub-id-type="pmid">38250038</pub-id><pub-id pub-id-type="pmcid">PMC10797289</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jakobsson</surname><given-names>V.</given-names></name><name name-style="western"><surname>Greifenstein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khong</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><article-title>Alpha-Peptide Receptor Radionuclide
Therapy Using Actinium-225 Labeled Somatostatin Receptor Agonists
and Antagonists</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><fpage>1034315</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.1034315</pub-id><pub-id pub-id-type="pmcid">PMC9767967</pub-id><pub-id pub-id-type="pmid">36569154</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Cavaco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valle</surname><given-names>J.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>J. D. G.</given-names></name><name name-style="western"><surname>Castanho</surname><given-names>M. A. R. B.</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>V.</given-names></name><article-title>DPepH3, an Improved Peptide Shuttle
for Receptor-Independent Transport Across the Blood-Brain Barrier</article-title><source>Curr. Pharm. Des.</source><year>2020</year><volume>26</volume><issue>13</issue><fpage>1495</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.2174/1381612826666200213094556</pub-id><pub-id pub-id-type="pmid">32053069</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Neves</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aires-Da-Silva</surname><given-names>F.</given-names></name><name name-style="western"><surname>Morais</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gaspar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>J. D. G.</given-names></name><name name-style="western"><surname>Castanho</surname><given-names>M. A. R. B.</given-names></name><article-title>Novel Peptides Derived from Dengue
Virus Capsid Protein Translocate Reversibly the Blood-Brain Barrier
through a Receptor-Free Mechanism</article-title><source>ACS Chem.
Biol.</source><year>2017</year><volume>12</volume><fpage>1257</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00087</pub-id><pub-id pub-id-type="pmid">28263555</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Banks</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Rhea</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>M. A.</given-names></name><article-title>The Penetration
of Therapeutics across the Blood-Brain Barrier: Classic Case Studies
and Clinical Implications</article-title><source>Cell Rep. Med.</source><year>2024</year><volume>5</volume><fpage>101760</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101760</pub-id><pub-id pub-id-type="pmid">39383873</pub-id><pub-id pub-id-type="pmcid">PMC11604479</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Rubbiani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Can</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kitanovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alborzinia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stefanopoulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kokoschka</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#246;nchgesang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sheldrick</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>W&#246;lfl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>I.</given-names></name><article-title>Comparative in Vitro Evaluation of
N-Heterocyclic Carbene Gold&#173;(I) Complexes of the Benzimidazolylidene
Type</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><issue>24</issue><fpage>8646</fpage><lpage>8657</lpage><pub-id pub-id-type="doi">10.1021/jm201220n</pub-id><pub-id pub-id-type="pmid">22039997</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Jagtiani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yeolekar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patravale</surname><given-names>V.</given-names></name><article-title>In Vitro Blood
Brain Barrier Models: An Overview</article-title><source>J. Controlled
Release</source><year>2022</year><volume>343</volume><fpage>13</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.01.011</pub-id><pub-id pub-id-type="pmid">35026351</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Woods</surname><given-names>B.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R. D. M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wragg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cavaco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>V. F. C.</given-names></name><name name-style="western"><surname>Gano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morais</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>J. D. G.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><article-title>Bioconjugate Supramolecular
Pd2+ Metallacages Penetrate the Blood Brain Barrier In Vitro and In
Vivo</article-title><source>Bioconjugate Chem.</source><year>2021</year><volume>32</volume><issue>7</issue><fpage>1399</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.0c00659</pub-id><pub-id pub-id-type="pmid">33440122</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Guarra</surname><given-names>F.</given-names></name><name name-style="western"><surname>Terenzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Passannante</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zangrando</surname><given-names>E.</given-names></name><name name-style="western"><surname>G&#243;mez-Vallejo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Biver</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gabbiani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Llop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salassa</surname><given-names>L.</given-names></name><article-title>124I Radiolabeling of a AuIII-NHC
Complex for In Vivo
Biodistribution Studies</article-title><source>Angew. Chem., Int.
Ed.</source><year>2020</year><volume>59</volume><issue>39</issue><fpage>17130</fpage><lpage>17136</lpage><pub-id pub-id-type="doi">10.1002/anie.202008046</pub-id><pub-id pub-id-type="pmcid">PMC7540067</pub-id><pub-id pub-id-type="pmid">32633820</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Tialiou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Reithofer</surname><given-names>M. R.</given-names></name><article-title>Current
Developments of N-Heterocyclic Carbene Au&#173;(I)/Au&#173;(III) Complexes toward
Cancer Treatment</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><fpage>1417</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10061417</pub-id><pub-id pub-id-type="pmid">35740438</pub-id><pub-id pub-id-type="pmcid">PMC9219884</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>B&#252;ssing</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karge</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lippmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Br&#246;nstrup</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>I.</given-names></name><article-title>Gold&#173;(I) and Gold&#173;(III) N-Heterocyclic
Carbene Complexes as Antibacterial
Agents and Inhibitors of Bacterial Thioredoxin Reductase</article-title><source>ChemMedChem</source><year>2021</year><volume>16</volume><issue>22</issue><fpage>3402</fpage><lpage>3409</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202100381</pub-id><pub-id pub-id-type="pmid">34268875</pub-id><pub-id pub-id-type="pmcid">PMC9290826</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Salorinne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Man</surname><given-names>R. W. Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Taki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nambo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crudden</surname><given-names>C. M.</given-names></name><article-title>Water-Soluble N-Heterocyclic Carbene-Protected Gold
Nanoparticles: Size-Controlled Synthesis, Stability, and Optical Properties</article-title><source>Angew. Chem., Int. Ed.</source><year>2017</year><volume>56</volume><issue>22</issue><fpage>6198</fpage><lpage>6202</lpage><pub-id pub-id-type="doi">10.1002/anie.201701605</pub-id><pub-id pub-id-type="pmid">28407403</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>